Changeflow GovPing Pharma & Drug Safety Bristol-Myers Squibb Patent - Manufacturing Pro...
Routine Notice Added Final

Bristol-Myers Squibb Patent - Manufacturing Process for Protein

Favicon for changeflow.com EPO Patent Bulletin - Peptides (C07K)
Published
Detected
Email

Summary

The European Patent Office published patent EP4196597A2 for Bristol-Myers Squibb Company, covering a manufacturing process for protein production. The patent lists five inventors and contains IPC classifications spanning C12P, C07K, C12N, and G01N categories. The patent is designated across 31 European states including major markets such as DE, FR, GB, IT, and ES.

What changed

EPO published patent EP4196597A2 for Bristol-Myers Squibb Company, covering manufacturing processes for protein production. The patent includes multiple IPC classifications related to peptide/protein preparation (C07K, C12P), cell culture (C12N), and analytical methods (G01N). Designated states include all major European markets.

For biotech and pharmaceutical companies engaged in protein manufacturing or related analytical methods, this patent may affect Freedom-to-Operate considerations. Companies should review their manufacturing processes and R&D programs to assess potential overlap with the granted claims. Potential licensing discussions with Bristol-Myers Squibb may be warranted for overlapping product development activities.

What to do next

  1. Review patent claims for Freedom-to-Operate analysis
  2. Monitor for potential licensing opportunities
  3. Assess impact on protein production R&D programs

Archived snapshot

Apr 8, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

MANUFACTURING PROCESS FOR PROTEIN

Publication EP4196597A2 Kind: A2 Apr 01, 2026

Applicants

Bristol-Myers Squibb Company

Inventors

LEWIS, Amanda Morgan, MASKAS, Daniel Robert, GARR, Eric Richard, WORRELL, Diane Kay, LUDWIG, Richard Thomas

IPC Classifications

C12P 21/00 20060101AFI20230313BHEP C12P 21/02 20060101ALI20230313BHEP C07K 14/705 20060101ALI20230313BHEP C12N 5/071 20100101ALI20230313BHEP G01N 21/64 20060101ALI20230313BHEP G01N 33/487 20060101ALI20230313BHEP G01N 33/58 20060101ALI20230313BHEP G01N 33/68 20060101ALI20230313BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4196597A2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Clinical investigators
Industry sector
3254.1 Biotechnology
Activity scope
Protein manufacturing processes Biopharmaceutical R&D Analytical method development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.